Immupharma
IMM · AIM · Health Care · mcap £25m · 4.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 15 Sep 26 | New peer-reviewed publication
Peer-reviewed publication reports P140 reduces steatohepatitis and fibrosis in preclinical MASH mouse model. |
−8.4% | |
| 15 Sep 26 | P140 International Patent Filing Update
ImmuPharma files international Patent Cooperation Treaty application for P140 precision medicine approach in autoimmune disease. |
−8.4% | |
| 15 Sep 26 | Results | Half-year Results
H1 2026 operating loss £1.1m, slightly improved from £1.2m prior year; raised £6.47m funding. |
−8.4% |
| 10 Aug 26 | Bioanalytical CRO partner for Kapiglucagon
Kymos Group selected as bioanalytical CRO partner for Kapiglucagon development program. |
−6.9% | |
| 22 Jul 26 | Thermo Fisher CDMO selected for Kapiglucagon pro
Thermo Fisher selected as drug product CDMO for Kapiglucagon program following competitive tender. |
−6.7% | |
| 25 Jun 26 | 2026 Result Of Annual General Meeting
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. |
−6.8% | |
| 25 Jun 26 | ImmuPharma appoints Bachem for Kapiglucagon API
ImmuPharma appoints Bachem as API manufacturing partner for Kapiglucagon diabetes program. |
−6.8% | |
| 24 Jun 26 | University of Murcia research relating to P140
University of Murcia published research on P140 peptide in glioblastoma; ImmuPharma notes awareness and supportive findings. |
−3.2% | |
| 04 Jun 26 | Incanthera plc – Corporate Update & Board Changes
ImmuPharma notes Incanthera's corporate update and board changes involving Tim McCarthy's departure. |
−3.7% | |
| 27 May 26 | Results | Final Results
Full-year loss narrowed to £1.8m; £6.47m fundraise completed; P140 autoimmune platform progressing with patent filing and commercial partnerships sought. |
−4.3% |
| 05 May 26 | IMM initiatesIND-Enabling Program for Kapiglucagon
ImmuPharma initiates IND-enabling program for Kapiglucagon diabetes treatment with FDA-focused regulatory strategy. |
−3.4% | |
| 09 Apr 26 | Board change | Chairman’s Open Letter to Shareholders
Shareholders approve £6 million Lanstead subscription and £468k WRAP retail offering; extends cash runway to H2 2028. |
+8.4% |
| 27 Mar 26 | P140 Program Update
P140 patent application receives supportive first examination report; new supporting study completed with positive results. |
+1.2% | |
| 23 Mar 26 | Fundraise | Result of WRAP Retail Offer and TVR
ImmuPharma raises £6.468m gross proceeds via subscription, WRAP retail offer and other share issuances. |
−3.9% |
| 18 Mar 26 | ‘Investor Meet Company’ presentation on 20 March
Company to present on Investor Meet Company platform on 20 March 2026. |
−8.3% | |
| 17 Mar 26 | Offer | WRAP Retail Offer for up to £1.5 million
Retail offer of up to £1.5 million at 6.0p per share, conditional on shareholder approval. |
−22.2% |
| 17 Mar 26 | Fundraise | P140 Update; Fundraise, Related Party Transaction
ImmuPharma raises £6m from Lanstead with up to £1.5m retail offer; accelerates Kapiglucagon development. |
−22.2% |
| 06 Jan 26 | Attending JPMorgan Conference & Biotech Showcase
ImmuPharma executives attending JP Morgan Healthcare Conference and Biotech Showcase 12-14 January 2026. |
−4.7% | |
| 24 Nov 25 | Corporate Update
P140 partnership deal completion pushed to 2026 from end 2025; cash runway extended to Q4 2026. |
−31.4% | |
| 27 Oct 25 | Immupharma Attending Bio-europe
CEO and two senior executives attending Bio-Europe Conference in Vienna, 3-5 November 2025. |
−3.4% | |
| 23 Oct 25 | Launch of Website; Corporate Update
ImmuPharma launches new website and updates on P140 platform strategy; pursuing partnership deals by end of 2025. |
+13.5% | |
| 13 Oct 25 | Board change | Appointment of Independent Non-Executive Director
Ketan Patel appointed as independent Non-Executive Director with immediate effect. |
−6.3% |
Company filings. Not investment advice.